Wegovy Pricing Snapshot: Retail $400–$570, Generic Seen Summer 2026

Current retail price band

Teletest lists Wegovy at $400–$570 per month for a 30-day supply across Canadian pharmacies, and notes the product is not listed on the Ontario Drug Benefit formulary [Source: teletest.ca/cost/drug/wegovy/]. A separate consumer guide reported a typical single-pen retail purchase of $540–$570 per month, with annual out-of-pocket cost reaching approximately $5,066 CAD at the maintenance dose [Source: ogaei.ca/blog/wegovy-cost-in-canada/]. The same guide cited a bulk three-pen purchase price of approximately $399 per pen [Source: ogaei.ca/blog/wegovy-cost-in-canada/].

One article reported a single-pen retail price up to $570 [Source: ogaei.ca/blog/wegovy-cost-in-canada/], though current pharmacy listings on GLP1Prices.ca place Wegovy at $270–$550 per month across verified pharmacies.

Insurance and employer coverage

With comprehensive private coverage, some patients pay as little as $25–$106 per month through co-payment arrangements [Source: ogaei.ca/blog/wegovy-cost-in-canada/]. As of 2026, approximately 31% of Canadian employers include GLP-1 medication coverage in their benefit plans, but 56% of employers offering coverage restrict it to diabetes management [Source: ogaei.ca/blog/wegovy-cost-in-canada/]. Less than 10% of Canadians currently have private insurance coverage for weight loss medications [Source: ogaei.ca/blog/wegovy-cost-in-canada/].

On the public side, no Canadian provincial health plan covers Wegovy when prescribed for weight loss as of January 2026 [Source: ogaei.ca/blog/wegovy-cost-in-canada/]. Negotiations between the pan-Canadian Pharmaceutical Alliance and Novo Nordisk concluded in December 2025 without agreement, with the manufacturer declining to negotiate on price [Source: ogaei.ca/blog/wegovy-cost-in-canada/]. Patients without private drug insurance may qualify for the Novo Nordisk Care program [Source: teletest.ca/cost/drug/wegovy/]. Patients can use our insurance coverage checker to evaluate options.

Generic timeline

Health Canada is reviewing nine submissions for generic versions of semaglutide [Source: cbc.ca/news/health/ozempic-glp1-health-canada-generic-9.7034498]. Canada is the only country where Novo Nordisk allowed the patent for its semaglutide drugs to expire, with regulatory exclusivity ending January 4 [Source: cbc.ca/news/health/ozempic-glp1-health-canada-generic-9.7034498]. Mark Johnson, a Health Canada spokesperson, said evaluating generic semaglutide drugs is more complex than many other medication approvals because semaglutide was originally developed using biological processes while generic versions can be made through simpler chemical means [Source: cbc.ca/news/health/ozempic-glp1-health-canada-generic-9.7034498].

Mina Tadrous, an associate professor at the Leslie Dan Faculty of Pharmacy at the University of Toronto, said summer would be a more likely window than January or February for approvals [Source: cbc.ca/news/health/ozempic-glp1-health-canada-generic-9.7034498]. Teletest projects a generic Wegovy at $40–$160 per month upon arrival in summer 2026 [Source: teletest.ca/cost/drug/wegovy/]. Readers can monitor progress via our generic semaglutide tracker.

Manufacturing-cost backdrop

A study released March 2026 estimated that a month's supply of semaglutide could cost as little as $3 to manufacture once off patent, according to researchers at Imperial College London and the University of Witwatersrand [Source: canadianaffairs.news/2026/03/08/anti-obesity-treatment-could-cost-as-little-as-3-per-month-study/]. The study identified 150 countries where semaglutide was never patented and noted the 160 jurisdictions where it will not be under patent account for 69% of people with Type 2 diabetes globally [Source: canadianaffairs.news/2026/03/08/anti-obesity-treatment-could-cost-as-little-as-3-per-month-study/]. The research was published directly rather than in a peer-reviewed journal [Source: canadianaffairs.news/2026/03/08/anti-obesity-treatment-could-cost-as-little-as-3-per-month-study/].

What this means for patients

• Retail Wegovy remains a four-figure annual expense for uninsured Canadians [Source: ogaei.ca/blog/wegovy-cost-in-canada/].
• Provincial plans do not list Wegovy for weight management [Source: teletest.ca/cost/drug/wegovy/].
• Health Canada's review of nine generic semaglutide submissions remains the key pricing variable [Source: cbc.ca/news/health/ozempic-glp1-health-canada-generic-9.7034498].

For comparisons across Ozempic, Rybelsus, Mounjaro, and Zepbound, see the broader product pages, or visit our FAQ.